CALGARY, Alberta, June 06, 2018 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE:XRX) (OTCQB:XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that the Company’s shares have been approved to commence trading on the OTCQB Venture Market under the symbol XRTXF effective June 7, 2018.
Trading in the Company’s shares on the OTCQB will provide a dealer market for XORTX shares and easy access to continuous disclosure documents giving investors in the United States greater access to invest in the Company’s shares. The OTCQB Market provides trading for 900 US and international companies through its SEC-registered OTC Link® ATS, which features over 100 broker-dealers. Quotes for XORTX’s US symbol are available directly at www.otcmarkets.com/stock/XRTXF/quote.
The Company’s shares will continue to trade on the Canadian Securities Exchange under the symbol XRX.
Dr. Allen Davidoff, President and CEO stated, “We are pleased to have been accepted for trading on the OTCQB Venture Market which we believe will increase XORTX’s exposure to US retail and institutional investors, increasing liquidity for shareholders. We anticipate that upcoming milestones and the increased investor base will work synergistically to the benefit of all shareholders.”
About XORTX Therapeutics Inc.
XORTX Therapeutics Inc. is a BioPharmaceutical company focused on developing innovative therapies to treat progressive kidney disease. XORTX has lead programs to develop treatments for progressive kidney disease due to diabetes, diabetic nephropathy and polycystic kidney disease. Secondary programs focus on developing therapies for health consequences that accompany pre-diabetes, diabetes and cardiovascular disease. Additional information on XORTX Therapeutics is available at www.xortx.com.
For further information, please contact:
The CSE has neither approved nor disapproved the contents of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.